{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:04:02Z","timestamp":1787108642815,"version":"build-2736575974"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40263-025-01212-5","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:44:14Z","timestamp":1755755054000},"page":"995-1009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nonseizure Outcomes in Dravet Syndrome: Potential Impact of Pharmacotherapy"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1049-5565","authenticated-orcid":false,"given":"Adriana","family":"Swindler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-4219","authenticated-orcid":false,"given":"Alexander","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Hendry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7728-6903","authenticated-orcid":false,"given":"Andreas","family":"Brunklaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"8","key":"1212_CR1","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/brain\/awz195","volume":"142","author":"JD Symonds","year":"2019","unstructured":"Symonds JD, Zuberi SM, Stewart K, et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain. 2019;142(8):2303\u201318. https:\/\/doi.org\/10.1093\/brain\/awz195.","journal-title":"Brain"},{"issue":"Suppl 2","key":"1212_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","volume":"52","author":"C Dravet","year":"2011","unstructured":"Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52(Suppl 2):3\u20139. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.02994.x.","journal-title":"Epilepsia"},{"issue":"Pt 8","key":"1212_CR3","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/brain\/aws151","volume":"135","author":"A Brunklaus","year":"2012","unstructured":"Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135(Pt 8):2329\u201336. https:\/\/doi.org\/10.1093\/brain\/aws151.","journal-title":"Brain"},{"key":"1212_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/1750-1172-8-176","volume":"8","author":"R Nabbout","year":"2013","unstructured":"Nabbout R, Chemaly N, Chipaux M, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8:176. https:\/\/doi.org\/10.1186\/1750-1172-8-176.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 2","key":"1212_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1528-1167.2011.03000.x","volume":"52","author":"F Ragona","year":"2011","unstructured":"Ragona F. Cognitive development in children with Dravet syndrome. Epilepsia. 2011;52(Suppl 2):39\u201343. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03000.x.","journal-title":"Epilepsia"},{"issue":"1","key":"1212_CR6","doi-asserted-by":"publisher","first-page":"fcae004","DOI":"10.1093\/braincomms\/fcae004","volume":"6","author":"T Feng","year":"2024","unstructured":"Feng T, Makiello P, Dunwoody B, et al. Long-term predictors of developmental outcome and disease burden in SCN1A-positive Dravet syndrome. Brain Commun. 2024;6(1):fcae004. https:\/\/doi.org\/10.1093\/braincomms\/fcae004.","journal-title":"Brain Commun."},{"issue":"Suppl 2","key":"1212_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1528-1167.2011.03001.x","volume":"52","author":"P Genton","year":"2011","unstructured":"Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. Epilepsia. 2011;52(Suppl 2):44\u20139. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03001.x.","journal-title":"Epilepsia"},{"key":"1212_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108661","volume":"130","author":"J Sullivan","year":"2022","unstructured":"Sullivan J, Deighton AM, Vila MC, et al. The clinical, economic, and humanistic burden of Dravet syndrome\u2014a systematic literature review. Epilepsy Behav. 2022;130: 108661. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108661.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1212_CR9","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1038\/s41598-023-30273-z","volume":"13","author":"A Gil-Nagel","year":"2023","unstructured":"Gil-Nagel A, Sanchez-Carpintero R, Villanueva V. Patient profile, management, and quality of life associated with Dravet syndrome: a cross-sectional, multicentre study of 80 patients in Spain. Sci Rep. 2023;13(1):3355. https:\/\/doi.org\/10.1038\/s41598-023-30273-z.","journal-title":"Sci Rep"},{"key":"1212_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109179","volume":"142","author":"A Strzelczyk","year":"2023","unstructured":"Strzelczyk A, Aledo-Serrano A, Coppola A, et al. The impact of epilepsy on quality of life: findings from a European survey. Epilepsy Behav. 2023;142: 109179. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109179.","journal-title":"Epilepsy Behav"},{"issue":"Pt A","key":"1212_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.yebeh.2016.09.007","volume":"64","author":"S Shmuely","year":"2016","unstructured":"Shmuely S, Sisodiya SM, Gunning WB, Sander JW, Thijs RD. Mortality in Dravet syndrome: a review. Epilepsy Behav. 2016;64(Pt A):69\u201374. https:\/\/doi.org\/10.1016\/j.yebeh.2016.09.007.","journal-title":"Epilepsy Behav"},{"issue":"7","key":"1212_CR12","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/epi.17274","volume":"63","author":"EC Wirrell","year":"2022","unstructured":"Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63(7):1761\u201377. https:\/\/doi.org\/10.1111\/epi.17274.","journal-title":"Epilepsia"},{"issue":"3","key":"1212_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. A Practical guide to the treatment of Dravet Syndrome with anti-seizure medication. CNS Drugs. 2022;36(3):217\u201337. https:\/\/doi.org\/10.1007\/s40263-022-00898-1.","journal-title":"CNS Drugs"},{"key":"1212_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109560","volume":"150","author":"B Bjurulf","year":"2024","unstructured":"Bjurulf B, Reilly C, Hallbook T. Caregiver reported behavior, sleep and quality of life in children with Dravet syndrome: a population-based study. Epilepsy Behav. 2024;150: 109560. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109560.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1212_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/epi4.12413","volume":"5","author":"K Heger","year":"2020","unstructured":"Heger K, Lund C, Larsen Burns M, et al. A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway. Epilepsia Open. 2020;5(3):432\u201341. https:\/\/doi.org\/10.1002\/epi4.12413.","journal-title":"Epilepsia Open."},{"issue":"6","key":"1212_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1086\/320609","volume":"68","author":"L Claes","year":"2001","unstructured":"Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68(6):1327\u201332. https:\/\/doi.org\/10.1086\/320609.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"1212_CR17","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1111\/epi.17015","volume":"62","author":"W Li","year":"2021","unstructured":"Li W, Schneider AL, Scheffer IE. Defining Dravet syndrome: an essential pre-requisite for precision medicine trials. Epilepsia. 2021;62(9):2205\u201317. https:\/\/doi.org\/10.1111\/epi.17015.","journal-title":"Epilepsia"},{"key":"1212_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109726","volume":"154","author":"A Postma","year":"2024","unstructured":"Postma A, Minderhoud CA, Otte WM, et al. Understanding neurodevelopmental trajectories and behavioral profiles in SCN1A-related epilepsy syndromes. Epilepsy Behav. 2024;154: 109726. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109726.","journal-title":"Epilepsy Behav"},{"issue":"7","key":"1212_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/epi.12652","volume":"55","author":"A Brunklaus","year":"2014","unstructured":"Brunklaus A, Zuberi SM. Dravet syndrome\u2014from epileptic encephalopathy to channelopathy. Epilepsia. 2014;55(7):979\u201384. https:\/\/doi.org\/10.1111\/epi.12652.","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"1212_CR20","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1111\/j.1528-1157.1998.tb05118.x","volume":"39","author":"R Guerrini","year":"1998","unstructured":"Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia. 1998;39(Suppl 3):S2-10. https:\/\/doi.org\/10.1111\/j.1528-1157.1998.tb05118.x.","journal-title":"Epilepsia"},{"issue":"6","key":"1212_CR21","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/epi.14191","volume":"59","author":"IM de Lange","year":"2018","unstructured":"de Lange IM, Gunning B, Sonsma ACM, et al. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes. Epilepsia. 2018;59(6):1154\u201365. https:\/\/doi.org\/10.1111\/epi.14191.","journal-title":"Epilepsia"},{"issue":"4","key":"1212_CR22","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/epi.17531","volume":"64","author":"P Makiello","year":"2023","unstructured":"Makiello P, Feng T, Dunwoody B, et al. Comorbidities and predictors of health-related quality of life in Dravet syndrome: a 10-year, prospective follow-up study. Epilepsia. 2023;64(4):1012\u201320. https:\/\/doi.org\/10.1111\/epi.17531.","journal-title":"Epilepsia"},{"key":"1212_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.110171","volume":"162","author":"D Samanta","year":"2025","unstructured":"Samanta D. A comprehensive review of evolving treatment strategies for Dravet syndrome: insights from randomized trials, meta-analyses, real-world evidence, and emerging therapeutic approaches. Epilepsy Behav. 2025;162: 110171. https:\/\/doi.org\/10.1016\/j.yebeh.2024.110171.","journal-title":"Epilepsy Behav"},{"key":"1212_CR24","unstructured":"Administration USFaD. Rare diseases: considerations for the development of drugs and biological products: Guidance for industry. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. 2025. https:\/\/www.fda.gov\/media\/119757\/download. Accessed 4 Jul 2025"},{"key":"1212_CR25","unstructured":"Agency EM. Procedural advice for orphan medicinal product designation: guidance for sponsors. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/procedural-advice-orphan-medicinal-product-designation-guidance-sponsors_en.pdf. Accessed 4 May 2025."},{"key":"1212_CR26","unstructured":"Agency EM. ICH reflection paper - proposed ICH guideline work to advance patient focused drug development (PFDD). European Medicines Agency. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-reflection-paper-proposed-ich-guideline-work-advance-patient-focused-drug-development-pfdd_en.pdf. Accessed 4 July 2025."},{"issue":"2","key":"1212_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/epi.17850","volume":"65","author":"MS Perry","year":"2024","unstructured":"Perry MS, Scheffer IE, Sullivan J, et al. Severe communication delays are independent of seizure burden and persist despite contemporary treatments in SCN1A+ Dravet syndrome: Insights from the ENVISION natural history study. Epilepsia. 2024;65(2):322\u201337. https:\/\/doi.org\/10.1111\/epi.17850.","journal-title":"Epilepsia"},{"issue":"Pt A","key":"1212_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108955","volume":"137","author":"J Sullivan","year":"2022","unstructured":"Sullivan J, Wirrell E, Knupp KG, et al. Interim results of adaptive functioning and neurodevelopment in BUTTERFLY\u2014an observational study of children and adolescents with Dravet syndrome. Epilepsy Behav. 2022;137(Pt A): 108955. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108955.","journal-title":"Epilepsy Behav"},{"key":"1212_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109604","volume":"151","author":"J Sullivan","year":"2024","unstructured":"Sullivan J, Wirrell E, Knupp KG, et al. Adaptive functioning and neurodevelopment in patients with Dravet syndrome: 12-month interim analysis of the BUTTERFLY observational study. Epilepsy Behav. 2024;151: 109604. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109604.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1212_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207958","volume":"102","author":"AT Berg","year":"2024","unstructured":"Berg AT, Ludwig NN, Wojnaroski M, et al. FDA patient-focused drug development guidances: considerations for trial readiness in rare developmental and epileptic encephalopathies. Neurology. 2024;102(1): e207958. https:\/\/doi.org\/10.1212\/WNL.0000000000207958.","journal-title":"Neurology"},{"issue":"8","key":"1212_CR31","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1111\/j.1528-1167.2011.03129.x","volume":"52","author":"A Brunklaus","year":"2011","unstructured":"Brunklaus A, Dorris L, Zuberi SM. Comorbidities and predictors of health-related quality of life in Dravet syndrome. Epilepsia. 2011;52(8):1476\u201382. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03129.x.","journal-title":"Epilepsia"},{"key":"1212_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.yebeh.2017.06.031","volume":"74","author":"N Villas","year":"2017","unstructured":"Villas N, Meskis MA, Goodliffe S. Dravet syndrome: characteristics, comorbidities, and caregiver concerns. Epilepsy Behav. 2017;74:81\u20136. https:\/\/doi.org\/10.1016\/j.yebeh.2017.06.031.","journal-title":"Epilepsy Behav"},{"key":"1212_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejpn.2024.10.010","volume":"53","author":"E Freeman-Jones","year":"2024","unstructured":"Freeman-Jones E, Wilson G, Eldred C, et al. Caregiver burden and therapeutic needs in Dravet syndrome\u2014a national UK cross-sectional questionnaire study. Eur J Paediatr Neurol. 2024;53:138\u201343. https:\/\/doi.org\/10.1016\/j.ejpn.2024.10.010.","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"1212_CR34","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/epi4.12832","volume":"8","author":"A Strzelczyk","year":"2023","unstructured":"Strzelczyk A, Lagae L, Wilmshurst JM, et al. Dravet syndrome: a systematic literature review of the illness burden. Epilepsia Open. 2023;8(4):1256\u201370. https:\/\/doi.org\/10.1002\/epi4.12832.","journal-title":"Epilepsia Open."},{"key":"1212_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107287","volume":"111","author":"AT Berg","year":"2020","unstructured":"Berg AT, Gaebler-Spira D, Wilkening G, et al. Nonseizure consequences of Dravet syndrome, KCNQ2-DEE, KCNB1-DEE, Lennox\u2013Gastaut syndrome, ESES: a functional framework. Epilepsy Behav. 2020;111: 107287. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107287.","journal-title":"Epilepsy Behav"},{"key":"1212_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106743","volume":"177","author":"DM Andrade","year":"2021","unstructured":"Andrade DM, Berg AT, Hood V, et al. Dravet syndrome: a quick transition guide for the adult neurologist. Epilepsy Res. 2021;177: 106743. https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106743.","journal-title":"Epilepsy Res"},{"issue":"12","key":"1212_CR37","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/dmcn.14990","volume":"63","author":"AT Berg","year":"2021","unstructured":"Berg AT, Coffman K, Gaebler-Spira D. Dysautonomia and functional impairment in rare developmental and epileptic encephalopathies: the other nervous system. Dev Med Child Neurol. 2021;63(12):1433\u201340. https:\/\/doi.org\/10.1111\/dmcn.14990.","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"1212_CR38","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1111\/epi.18329","volume":"66","author":"A Selvarajah","year":"2025","unstructured":"Selvarajah A, Sabo A, Gorodetsky C, et al. Dravet syndrome: from neurodevelopmental to neurodegenerative disease? Epilepsia. 2025;66(6):1975\u201387. https:\/\/doi.org\/10.1111\/epi.18329.","journal-title":"Epilepsia"},{"key":"1212_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109958","volume":"158","author":"S Giorgi","year":"2024","unstructured":"Giorgi S, Auvin S, Schoonjans AS, et al. A tool for Dravet syndrome-associated neuropsychiatric comorbidities evaluation (DANCE). Epilepsy Behav. 2024;158: 109958. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109958.","journal-title":"Epilepsy Behav"},{"key":"1212_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107079","volume":"108","author":"JS Jansson","year":"2020","unstructured":"Jansson JS, Hallbook T, Reilly C. Intellectual functioning and behavior in Dravet syndrome: a systematic review. Epilepsy Behav. 2020;108: 107079. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107079.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"1212_CR41","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/dmcn.15495","volume":"65","author":"C Reilly","year":"2023","unstructured":"Reilly C, Bjurulf B, Hallbook T. Intellectual functioning and adaptive behaviour in children with Dravet syndrome: a population-based study. Dev Med Child Neurol. 2023;65(6):831\u20137. https:\/\/doi.org\/10.1111\/dmcn.15495.","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"1212_CR42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/epi.13639","volume":"58","author":"A Ishii","year":"2017","unstructured":"Ishii A, Watkins JC, Chen D, Hirose S, Hammer MF. Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with Dravet syndrome. Epilepsia. 2017;58(2):282\u201390. https:\/\/doi.org\/10.1111\/epi.13639.","journal-title":"Epilepsia"},{"issue":"1","key":"1212_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/epi4.12281","volume":"4","author":"L Ouss","year":"2019","unstructured":"Ouss L, Leunen D, Laschet J, et al. Autism spectrum disorder and cognitive profile in children with Dravet syndrome: delineation of a specific phenotype. Epilepsia Open. 2019;4(1):40\u201353. https:\/\/doi.org\/10.1002\/epi4.12281.","journal-title":"Epilepsia Open."},{"issue":"11","key":"1212_CR44","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/dmcn.15937","volume":"66","author":"C Reilly","year":"2024","unstructured":"Reilly C, Bjurulf B, Hallbook T. Autism and attention-deficit\/hyperactivity disorder in children with Dravet syndrome: a population-based study. Dev Med Child Neurol. 2024;66(11):1457\u201365. https:\/\/doi.org\/10.1111\/dmcn.15937.","journal-title":"Dev Med Child Neurol"},{"issue":"10","key":"1212_CR45","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs. 2022;36(10):1079\u2013111. https:\/\/doi.org\/10.1007\/s40263-022-00955-9.","journal-title":"CNS Drugs"},{"issue":"2","key":"1212_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1076\/chin.8.2.71.8724","volume":"8","author":"P Anderson","year":"2002","unstructured":"Anderson P. Assessment and development of executive function (EF) during childhood. Child Neuropsychol. 2002;8(2):71\u201382. https:\/\/doi.org\/10.1076\/chin.8.2.71.8724.","journal-title":"Child Neuropsychol"},{"key":"1212_CR47","volume-title":"Psychological and developmental assessment","author":"GAIP Gioia","year":"2001","unstructured":"Gioia GAIP, Guy SC. Assessment of executive function in children with neurological impairments. In: Simeonsson RRS, editor. Psychological and developmental assessment. New York: The Guilford Press; 2001."},{"issue":"2","key":"1212_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12160-009-9097-4","volume":"37","author":"Y Suchy","year":"2009","unstructured":"Suchy Y. Executive functioning: overview, assessment, and research issues for non-neuropsychologists. Ann Behav Med. 2009;37(2):106\u201316. https:\/\/doi.org\/10.1007\/s12160-009-9097-4.","journal-title":"Ann Behav Med"},{"issue":"4","key":"1212_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1076\/chin.8.4.249.13513","volume":"8","author":"GA Gioia","year":"2002","unstructured":"Gioia GA, Isquith PK, Retzlaff PD, Espy KA. Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychol. 2002;8(4):249\u201357. https:\/\/doi.org\/10.1076\/chin.8.4.249.13513.","journal-title":"Child Neuropsychol"},{"issue":"10216","key":"1212_CR50","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(19)32500-0.","journal-title":"Lancet"},{"issue":"Pt A","key":"1212_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108024","volume":"121","author":"KI Bishop","year":"2021","unstructured":"Bishop KI, Isquith PK, Gioia GA, et al. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: analysis from a phase 3 long-term extension study in children\/young adults with Dravet syndrome. Epilepsy Behav. 2021;121(Pt A): 108024. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108024.","journal-title":"Epilepsy Behav"},{"key":"1212_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108994","volume":"138","author":"KI Bishop","year":"2023","unstructured":"Bishop KI, Isquith PK, Gioia GA, et al. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (< 5 years) with Dravet syndrome: a critical period for early neurodevelopment. Epilepsy Behav. 2023;138: 108994. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108994.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1212_CR53","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","volume":"77","author":"R Nabbout","year":"2020","unstructured":"Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4113.","journal-title":"JAMA Neurol"},{"issue":"10","key":"1212_CR54","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1111\/epi.17737","volume":"64","author":"J Sullivan","year":"2023","unstructured":"Sullivan J, Lagae L, Cross JH, et al. Fenfluramine in the treatment of Dravet syndrome: results of a third randomized, placebo-controlled clinical trial. Epilepsia. 2023;64(10):2653\u201366. https:\/\/doi.org\/10.1111\/epi.17737.","journal-title":"Epilepsia"},{"issue":"2","key":"1212_CR55","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1111\/epi.17854","volume":"65","author":"N Pietrafusa","year":"2024","unstructured":"Pietrafusa N, Trivisano M, Casellato S, et al. Fenfluramine below the age of 2 years in Dravet syndrome: what about safety and efficacy? Epilepsia. 2024;65(2):e7\u201313. https:\/\/doi.org\/10.1111\/epi.17854.","journal-title":"Epilepsia"},{"key":"1212_CR56","volume-title":"The Griffiths Mental Development Scales from birth to 2 years. Manual. The 1996 revision","author":"R Griffiths","year":"1996","unstructured":"Griffiths R. The Griffiths Mental Development Scales from birth to 2 years. Manual. The 1996 revision. London: Association for Research in Infant and Child Development; 1996."},{"issue":"1","key":"1212_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejpn.2010.09.003","volume":"15","author":"N Zamponi","year":"2011","unstructured":"Zamponi N, Passamonti C, Cappanera S, Petrelli C. Clinical course of young patients with Dravet syndrome after vagal nerve stimulation. Eur J Paediatr Neurol. 2011;15(1):8\u201314. https:\/\/doi.org\/10.1016\/j.ejpn.2010.09.003.","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"1212_CR58","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1177\/0883073816687221","volume":"32","author":"SP Fulton","year":"2017","unstructured":"Fulton SP, Van Poppel K, McGregor AL, Mudigoudar B, Wheless JW. Vagus nerve stimulation in intractable epilepsy associated with SCN1A gene abnormalities. J Child Neurol. 2017;32(5):494\u20138. https:\/\/doi.org\/10.1177\/0883073816687221.","journal-title":"J Child Neurol"},{"key":"1212_CR59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pediatrneurol.2024.12.012","volume":"164","author":"Z Wei","year":"2025","unstructured":"Wei Z, Liu T, Kuang S, Wang J, Liang S. Effectiveness of vagus nerve stimulation in patients with Dravet syndrome: a case series and meta-analysis. Pediatr Neurol. 2025;164:105\u201314. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.12.012.","journal-title":"Pediatr Neurol"},{"key":"1212_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109553","volume":"150","author":"C Ballesteros-Sayas","year":"2024","unstructured":"Ballesteros-Sayas C, Munoz-Montero A, Giorgi S, et al. Non-pharmacological therapeutic needs in people with Dravet syndrome. Epilepsy Behav. 2024;150: 109553. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109553.","journal-title":"Epilepsy Behav"},{"key":"1212_CR61","volume-title":"The Vineland Adaptive Behavior Scales","author":"SSCD Sparrow","year":"1989","unstructured":"Sparrow SSCD. The Vineland Adaptive Behavior Scales. Boston: Allyn & Bacon; 1989."},{"key":"1212_CR62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.yebeh.2013.11.021","volume":"31","author":"N Villeneuve","year":"2014","unstructured":"Villeneuve N, Laguitton V, Viellard M, et al. Cognitive and adaptive evaluation of 21 consecutive patients with Dravet syndrome. Epilepsy Behav. 2014;31:143\u20138. https:\/\/doi.org\/10.1016\/j.yebeh.2013.11.021.","journal-title":"Epilepsy Behav"},{"issue":"7","key":"1212_CR63","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMc1708349","volume":"377","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;377(7):699\u2013700. https:\/\/doi.org\/10.1056\/NEJMc1708349.","journal-title":"N Engl J Med"},{"issue":"5","key":"1212_CR64","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","volume":"77","author":"I Miller","year":"2020","unstructured":"Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(5):613\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0073.","journal-title":"JAMA Neurol"},{"key":"1212_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110381","volume":"167","author":"C Condon","year":"2025","unstructured":"Condon C, Parkerson KA, Dandurand A, et al. Qualitative evaluation of meaningful change in Dravet syndrome as measured by the Vineland-3: caregiver and clinician perspectives. Epilepsy Behav. 2025;167: 110381. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110381.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1212_CR66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/dmcn.13591","volume":"60","author":"L Lagae","year":"2018","unstructured":"Lagae L, Brambilla I, Mingorance A, Gibson E, Battersby A. Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey. Dev Med Child Neurol. 2018;60(1):63\u201372. https:\/\/doi.org\/10.1111\/dmcn.13591.","journal-title":"Dev Med Child Neurol"},{"key":"1212_CR67","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.yebeh.2015.10.027","volume":"54","author":"D Chieffo","year":"2016","unstructured":"Chieffo D, Battaglia D, Lucibello S, et al. Disorders of early language development in Dravet syndrome. Epilepsy Behav. 2016;54:30\u20133. https:\/\/doi.org\/10.1016\/j.yebeh.2015.10.027.","journal-title":"Epilepsy Behav"},{"issue":"8","key":"1212_CR68","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000003635","volume":"88","author":"SJ Turner","year":"2017","unstructured":"Turner SJ, Brown A, Arpone M, Anderson V, Morgan AT, Scheffer IE. Dysarthria and broader motor speech deficits in Dravet syndrome. Neurology. 2017;88(8):743\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000003635.","journal-title":"Neurology"},{"issue":"9","key":"1212_CR69","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1017\/S0012162206001629","volume":"48","author":"KJ Nolan","year":"2006","unstructured":"Nolan KJ, Camfield CS, Camfield PR. Coping with Dravet syndrome: parental experiences with a catastrophic epilepsy. Dev Med Child Neurol. 2006;48(9):761\u20135. https:\/\/doi.org\/10.1017\/S0012162206001629.","journal-title":"Dev Med Child Neurol"},{"key":"1212_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110459","volume":"170","author":"M Delporte","year":"2025","unstructured":"Delporte M, Verbeeck J, Brambilla I, et al. Dravet syndrome: Insights into seizure and speech progression from registry data. Epilepsy Behav. 2025;170: 110459. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110459.","journal-title":"Epilepsy Behav"},{"issue":"7","key":"1212_CR71","doi-asserted-by":"publisher","first-page":"CD006937","DOI":"10.1002\/14651858.CD006937.pub3","volume":"7","author":"L Pennington","year":"2016","unstructured":"Pennington L, Parker NK, Kelly H, Miller N. Speech therapy for children with dysarthria acquired before three years of age. Cochrane Database Syst Rev. 2016;7(7):CD006937. https:\/\/doi.org\/10.1002\/14651858.CD006937.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1212_CR72","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.seizure.2025.04.017","volume":"130","author":"MS Perry","year":"2025","unstructured":"Perry MS, Dixon-Salazar T, Meskis MA, et al. Caregiver-reported non-seizure and seizure outcomes with cannabidiol and clobazam in patients aged >\/=2 years with Lennox\u2013Gastaut syndrome or Dravet syndrome: a subgroup analysis of the BECOME survey. Seizure. 2025;130:32\u201340. https:\/\/doi.org\/10.1016\/j.seizure.2025.04.017.","journal-title":"Seizure."},{"issue":"1","key":"1212_CR73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/epi4.12569","volume":"7","author":"E Cardenal-Munoz","year":"2022","unstructured":"Cardenal-Munoz E, Auvin S, Villanueva V, et al. Guidance on Dravet syndrome from infant to adult care: road map for treatment planning in Europe. Epilepsia Open. 2022;7(1):11\u201326. https:\/\/doi.org\/10.1002\/epi4.12569.","journal-title":"Epilepsia Open."},{"issue":"7","key":"1212_CR74","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1111\/j.1528-1167.2011.03107.x","volume":"52","author":"R Nabbout","year":"2011","unstructured":"Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52(7):e54\u20137. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03107.x.","journal-title":"Epilepsia"},{"issue":"4","key":"1212_CR75","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-2869.1996.00251.x","volume":"5","author":"O Bruni","year":"1996","unstructured":"Bruni O, Ottaviano S, Guidetti V, et al. The Sleep Disturbance Scale for Children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. J Sleep Res. 1996;5(4):251\u201361. https:\/\/doi.org\/10.1111\/j.1365-2869.1996.00251.x.","journal-title":"J Sleep Res"},{"issue":"1","key":"1212_CR76","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejpn.2018.09.012","volume":"23","author":"AS Schoonjans","year":"2019","unstructured":"Schoonjans AS, De Keersmaecker S, Van Bouwel M, Ceulemans B. More daytime sleepiness and worse quality of sleep in patients with Dravet Syndrome compared to other epilepsy patients. Eur J Paediatr Neurol. 2019;23(1):61\u20139. https:\/\/doi.org\/10.1016\/j.ejpn.2018.09.012.","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"1212_CR77","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/dmcn.13601","volume":"60","author":"SH Licheni","year":"2018","unstructured":"Licheni SH, McMahon JM, Schneider AL, Davey MJ, Scheffer IE. Sleep problems in Dravet syndrome: a modifiable comorbidity. Dev Med Child Neurol. 2018;60(2):192\u20138. https:\/\/doi.org\/10.1111\/dmcn.13601.","journal-title":"Dev Med Child Neurol"},{"issue":"10","key":"1212_CR78","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.5664\/jcsm.7376","volume":"14","author":"KA Myers","year":"2018","unstructured":"Myers KA, Davey MJ, Ching M, et al. Randomized controlled trial of melatonin for sleep disturbance in Dravet syndrome: the DREAMS study. J Clin Sleep Med. 2018;14(10):1697\u2013704. https:\/\/doi.org\/10.5664\/jcsm.7376.","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"1212_CR79","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ene.13195","volume":"24","author":"A Schoonjans","year":"2017","unstructured":"Schoonjans A, Paelinck BP, Marchau F, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol. 2017;24(2):309\u201314. https:\/\/doi.org\/10.1111\/ene.13195.","journal-title":"Eur J Neurol"},{"key":"1212_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106976","volume":"185","author":"MP Jensen","year":"2022","unstructured":"Jensen MP, Gammaitoni AR, Galer BS, Salem R, Wilkie D, Amtmann D. Fenfluramine treatment for Dravet syndrome: real-world benefits on quality of life from the caregiver perspective. Epilepsy Res. 2022;185: 106976. https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106976.","journal-title":"Epilepsy Res"},{"key":"1212_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107091","volume":"190","author":"MP Jensen","year":"2023","unstructured":"Jensen MP, Gammaitoni AR, Salem R, Wilkie D, Lothe A, Amtmann D. Fenfluramine treatment for Dravet syndrome: caregiver- and clinician-reported benefits on the quality of life of patients, caregivers, and families living in Germany, Spain, Italy, and the United Kingdom. Epilepsy Res. 2023;190: 107091. https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107091.","journal-title":"Epilepsy Res"},{"key":"1212_CR82","first-page":"108","volume":"25","author":"L Kauppila","year":"2018","unstructured":"Kauppila L, Amorim I, Bentes C, Peralta R. Trazodone: a new antiepileptic drug for Dravet syndrome? Eur J Neurol. 2018;25:108\u2013108.","journal-title":"Eur J Neurol"},{"key":"1212_CR83","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18451","author":"A Cossu","year":"2025","unstructured":"Cossu A, Proietti J, Ghobert L, et al. Seizures influence sleep macrostructure and the sleep-wake circadian rhythm in Dravet syndrome. Epilepsia. 2025. https:\/\/doi.org\/10.1111\/epi.18451.","journal-title":"Epilepsia"},{"key":"1212_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107280","volume":"200","author":"AT Berg","year":"2024","unstructured":"Berg AT, Dixon-Salazar T, Meskis MA, Danese SR, Le NMD, Perry MS. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox\u2013Gastaut syndrome and Dravet syndrome from the BECOME survey. Epilepsy Res. 2024;200: 107280. https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107280.","journal-title":"Epilepsy Res"},{"issue":"11","key":"1212_CR85","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s40263-021-00867-0","volume":"35","author":"KA Klotz","year":"2021","unstructured":"Klotz KA, Grob D, Schonberger J, et al. Effect of cannabidiol on interictal epileptiform activity and sleep architecture in children with intractable epilepsy: a prospective open-label study. CNS Drugs. 2021;35(11):1207\u201315. https:\/\/doi.org\/10.1007\/s40263-021-00867-0.","journal-title":"CNS Drugs"},{"issue":"8","key":"1212_CR86","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/dmcn.14147","volume":"61","author":"K Verheyen","year":"2019","unstructured":"Verheyen K, Verbecque E, Ceulemans B, Schoonjans AS, Van De Walle P, Hallemans A. Motor development in children with Dravet syndrome. Dev Med Child Neurol. 2019;61(8):950\u20136. https:\/\/doi.org\/10.1111\/dmcn.14147.","journal-title":"Dev Med Child Neurol"},{"issue":"7","key":"1212_CR87","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1001\/archneurol.2011.3275","volume":"69","author":"JM Rodda","year":"2012","unstructured":"Rodda JM, Scheffer IE, McMahon JM, Berkovic SF, Graham HK. Progressive gait deterioration in adolescents with Dravet syndrome. Arch Neurol. 2012;69(7):873\u20138. https:\/\/doi.org\/10.1001\/archneurol.2011.3275.","journal-title":"Arch Neurol"},{"issue":"5","key":"1212_CR88","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/00004694-200409000-00011","volume":"24","author":"HK Graham","year":"2004","unstructured":"Graham HK, Harvey A, Rodda J, Nattrass GR, Pirpiris M. The Functional Mobility Scale (FMS). J Pediatr Orthop. 2004;24(5):514\u201320. https:\/\/doi.org\/10.1097\/00004694-200409000-00011.","journal-title":"J Pediatr Orthop"},{"key":"1212_CR89","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.yebeh.2018.09.041","volume":"90","author":"IM de Lange","year":"2019","unstructured":"de Lange IM, Gunning B, Sonsma ACM, et al. Outcomes and comorbidities of SCN1A-related seizure disorders. Epilepsy Behav. 2019;90:252\u20139. https:\/\/doi.org\/10.1016\/j.yebeh.2018.09.041.","journal-title":"Epilepsy Behav"},{"issue":"10","key":"1212_CR90","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/dmcn.15561","volume":"65","author":"K Verheyen","year":"2023","unstructured":"Verheyen K, Wyers L, Lambrecht E, et al. Functional mobility in children and young adults with Dravet syndrome. Dev Med Child Neurol. 2023;65(10):1343\u201356. https:\/\/doi.org\/10.1111\/dmcn.15561.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"1212_CR91","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ejpn.2019.03.003","volume":"23","author":"L Wyers","year":"2019","unstructured":"Wyers L, Van de Walle P, Hoornweg A, et al. Gait deviations in patients with Dravet syndrome: a systematic review. Eur J Paediatr Neurol. 2019;23(3):357\u201367. https:\/\/doi.org\/10.1016\/j.ejpn.2019.03.003.","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"1212_CR92","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.ejpn.2019.09.010","volume":"23","author":"R Di Marco","year":"2019","unstructured":"Di Marco R, Hallemans A, Bellon G, et al. Gait abnormalities in people with Dravet syndrome: a cross-sectional multi-center study. Eur J Paediatr Neurol. 2019;23(6):808\u201318. https:\/\/doi.org\/10.1016\/j.ejpn.2019.09.010.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"1212_CR93","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1212\/WNL.0000000000002859","volume":"87","author":"C Gitiaux","year":"2016","unstructured":"Gitiaux C, Chemaly N, Quijano-Roy S, et al. Motor neuropathy contributes to crouching in patients with Dravet syndrome. Neurology. 2016;87(3):277\u201381. https:\/\/doi.org\/10.1212\/WNL.0000000000002859.","journal-title":"Neurology"},{"issue":"22","key":"1212_CR94","doi-asserted-by":"publisher","first-page":"e2204","DOI":"10.1212\/WNL.0000000000200341","volume":"98","author":"A Selvarajah","year":"2022","unstructured":"Selvarajah A, Gorodetsky C, Marques P, et al. Progressive worsening of gait and motor abnormalities in older adults with Dravet syndrome. Neurology. 2022;98(22):e2204\u201310. https:\/\/doi.org\/10.1212\/WNL.0000000000200341.","journal-title":"Neurology"},{"issue":"3","key":"1212_CR95","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1111\/epi.13692","volume":"58","author":"D Aljaafari","year":"2017","unstructured":"Aljaafari D, Fasano A, Nascimento FA, Lang AE, Andrade DM. Adult motor phenotype differentiates Dravet syndrome from Lennox\u2013Gastaut syndrome and links SCN1A to early onset parkinsonian features. Epilepsia. 2017;58(3):e44\u20138. https:\/\/doi.org\/10.1111\/epi.13692.","journal-title":"Epilepsia"},{"issue":"24","key":"1212_CR96","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1212\/WNL.0000000000000521","volume":"82","author":"A Fasano","year":"2014","unstructured":"Fasano A, Borlot F, Lang AE, Andrade DM. Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. Neurology. 2014;82(24):2250\u20131. https:\/\/doi.org\/10.1212\/WNL.0000000000000521.","journal-title":"Neurology"},{"issue":"13","key":"1212_CR97","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1212\/WNL.0000000000008171","volume":"93","author":"L Deuel","year":"2019","unstructured":"Deuel L, Collins AE, Maa EH, Barr JP, Kern DS. Dravet syndrome and parkinsonism: a case report investigating the dopaminergic system. Neurology. 2019;93(13):595\u20136. https:\/\/doi.org\/10.1212\/WNL.0000000000008171.","journal-title":"Neurology"},{"issue":"5","key":"1212_CR98","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/epi.17888","volume":"65","author":"T Suzuki","year":"2024","unstructured":"Suzuki T, Natsume J, Ito Y, et al. Effect of levodopa on pathological gait in Dravet syndrome: a randomized crossover trial using three-dimensional gait analysis. Epilepsia. 2024;65(5):1304\u201313. https:\/\/doi.org\/10.1111\/epi.17888.","journal-title":"Epilepsia"},{"issue":"4","key":"1212_CR99","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/dmcn.14738","volume":"63","author":"K Verheyen","year":"2021","unstructured":"Verheyen K, Wyers L, Del Felice A, et al. Independent walking and cognitive development in preschool children with Dravet syndrome. Dev Med Child Neurol. 2021;63(4):472\u20139. https:\/\/doi.org\/10.1111\/dmcn.14738.","journal-title":"Dev Med Child Neurol"},{"issue":"7","key":"1212_CR100","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Movement Disorder Society Task Force on Rating Scales for Parkinson's D","year":"2003","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s D. The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738\u201350. https:\/\/doi.org\/10.1002\/mds.10473.","journal-title":"Mov Disord"},{"issue":"11","key":"1212_CR101","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/epi.16690","volume":"61","author":"N Specchio","year":"2020","unstructured":"Specchio N, Pietrafusa N, Doccini V, et al. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a real-world study. Epilepsia. 2020;61(11):2405\u201314. https:\/\/doi.org\/10.1111\/epi.16690.","journal-title":"Epilepsia"},{"issue":"10","key":"1212_CR102","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1111\/epi.17034","volume":"62","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk A, Pringsheim M, Mayer T, et al. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: compassionate use program in Germany. Epilepsia. 2021;62(10):2518\u201327. https:\/\/doi.org\/10.1111\/epi.17034.","journal-title":"Epilepsia"},{"issue":"1","key":"1212_CR103","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41687-024-00829-2","volume":"9","author":"JS Andrews","year":"2025","unstructured":"Andrews JS, Shah D, Nacson A, et al. Development and refinement of the clinical global impression of improvement for non-seizure symptoms measure in Dravet syndrome and Lennox\u2013Gastaut syndrome. J Patient Rep Outcomes. 2025;9(1):24. https:\/\/doi.org\/10.1186\/s41687-024-00829-2.","journal-title":"J Patient Rep Outcomes."},{"issue":"6\u20137","key":"1212_CR104","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/08830738231185241","volume":"38","author":"J Marshall","year":"2023","unstructured":"Marshall J, Skrobanski H, Moore-Ramdin L, Kornalska K, Swinburn P, Bowditch S. Caregivers\u2019 perspectives on the impact of cannabidiol (CBD) treatment for Dravet and Lennox\u2013Gastaut syndromes: a multinational qualitative study. J Child Neurol. 2023;38(6\u20137):394\u2013406. https:\/\/doi.org\/10.1177\/08830738231185241.","journal-title":"J Child Neurol"},{"key":"1212_CR105","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3389\/fneur.2019.00625","volume":"10","author":"X Tian","year":"2019","unstructured":"Tian X, Chen J, Zhang J, et al. The efficacy of ketogenic diet in 60 Chinese patients with Dravet syndrome. Front Neurol. 2019;10:625. https:\/\/doi.org\/10.3389\/fneur.2019.00625.","journal-title":"Front Neurol"},{"key":"1212_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2023.111976","volume":"110","author":"M Yu","year":"2023","unstructured":"Yu M, Li H, Sun D, et al. The ketogenic diet for Dravet syndrome: a multicenter retrospective study. Nutrition. 2023;110: 111976. https:\/\/doi.org\/10.1016\/j.nut.2023.111976.","journal-title":"Nutrition"},{"key":"1212_CR107","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yebeh.2018.12.016","volume":"92","author":"F Liu","year":"2019","unstructured":"Liu F, Peng J, Zhu C, et al. Efficacy of the ketogenic diet in Chinese children with Dravet syndrome: a focus on neuropsychological development. Epilepsy Behav. 2019;92:98\u2013102. https:\/\/doi.org\/10.1016\/j.yebeh.2018.12.016.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1212_CR108","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/01942630903454930","volume":"30","author":"AR Harvey","year":"2010","unstructured":"Harvey AR, Morris ME, Graham HK, Wolfe R, Baker R. Reliability of the functional mobility scale for children with cerebral palsy. Phys Occup Ther Pediatr. 2010;30(2):139\u201349. https:\/\/doi.org\/10.3109\/01942630903454930.","journal-title":"Phys Occup Ther Pediatr"},{"key":"1212_CR109","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00003086-197707000-00006","volume":"126","author":"WJ Kane","year":"1977","unstructured":"Kane WJ. Scoliosis prevalence: a call for a statement of terms. Clin Orthop Relat Res. 1977;126:43\u20136.","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"1212_CR110","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1230","volume":"137","author":"JB Carr 2nd","year":"2016","unstructured":"Carr JB 2nd, Yang S, Lather LA. Pediatric pes planus: a state-of-the-art review. Pediatrics. 2016;137(3): e20151230. https:\/\/doi.org\/10.1542\/peds.2015-1230.","journal-title":"Pediatrics"},{"issue":"1","key":"1212_CR111","doi-asserted-by":"publisher","first-page":"20242","DOI":"10.1038\/s41598-021-98517-4","volume":"11","author":"CH Huang","year":"2021","unstructured":"Huang CH, Hung PL, Fan PC, et al. Clinical spectrum and the comorbidities of Dravet syndrome in Taiwan and the possible molecular mechanisms. Sci Rep. 2021;11(1):20242. https:\/\/doi.org\/10.1038\/s41598-021-98517-4.","journal-title":"Sci Rep"},{"issue":"4","key":"1212_CR112","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00590-024-03903-z","volume":"34","author":"A Adhiyaman","year":"2024","unstructured":"Adhiyaman A, Tracey OC, Zucker C, Wisch J, Widmann RF, Heyer JH. Utilizing robotic-assisted navigation for pelvic instrumentation in pediatric patients with neuromuscular scoliosis: a technical note and case series. Eur J Orthop Surg Traumatol. 2024;34(4):2205\u201311. https:\/\/doi.org\/10.1007\/s00590-024-03903-z.","journal-title":"Eur J Orthop Surg Traumatol"},{"issue":"7","key":"1212_CR113","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","volume":"53","author":"B Ceulemans","year":"2012","unstructured":"Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131\u20139. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03495.x.","journal-title":"Epilepsia"},{"key":"1212_CR114","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.16252","author":"Y Kitamura","year":"2025","unstructured":"Kitamura Y, Ohyabu H, Miura T, et al. Safety and effectiveness of stiripentol in patients with Dravet syndrome: a prospective, 3-year, postmarketing surveillance study. Dev Med Child Neurol. 2025. https:\/\/doi.org\/10.1111\/dmcn.16252.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"1212_CR115","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/epi.18241","volume":"66","author":"A Boncristiano","year":"2025","unstructured":"Boncristiano A, Balestrini S, Doccini V, et al. Fenfluramine treatment for Dravet syndrome: long term real-world analysis demonstrates safety and reduced health care burden. Epilepsia. 2025;66(4):1110\u20138. https:\/\/doi.org\/10.1111\/epi.18241.","journal-title":"Epilepsia"},{"key":"1212_CR116","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2017.06.008","volume":"76","author":"KG Knupp","year":"2017","unstructured":"Knupp KG, Scarbro S, Wilkening G, Juarez-Colunga E, Kempe A, Dempsey A. Parental perception of comorbidities in children with Dravet syndrome. Pediatr Neurol. 2017;76:60\u20135. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.06.008.","journal-title":"Pediatr Neurol"},{"key":"1212_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109361","volume":"146","author":"CA Minderhoud","year":"2023","unstructured":"Minderhoud CA, Postma A, Jansen FE, et al. Gastrointestinal and eating problems in SCN1A-related seizure disorders. Epilepsy Behav. 2023;146: 109361. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109361.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1212_CR118","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/epi.18179","volume":"66","author":"A Laliberte","year":"2025","unstructured":"Laliberte A, Siafa L, Soufi A, et al. Eating habits and behaviors in children with Dravet syndrome: a case\u2013control study. Epilepsia. 2025;66(1):e1\u20136. https:\/\/doi.org\/10.1111\/epi.18179.","journal-title":"Epilepsia"},{"issue":"3","key":"1212_CR119","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200288","volume":"14","author":"LM Clayton","year":"2024","unstructured":"Clayton LM, Azadi B, Eldred C, Wilson G, Robinson R, Sisodiya SM. Feeding difficulties and gastrostomy in Dravet syndrome: a UK-wide survey and 2-center experience. Neurol Clin Pract. 2024;14(3): e200288. https:\/\/doi.org\/10.1212\/CPJ.0000000000200288.","journal-title":"Neurol Clin Pract."},{"key":"1212_CR120","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.seizure.2017.09.021","volume":"52","author":"K Eschbach","year":"2017","unstructured":"Eschbach K, Scarbro S, Juarez-Colunga E, Allen V, Hsu S, Knupp K. Growth and endocrine function in children with Dravet syndrome. Seizure. 2017;52:117\u201322. https:\/\/doi.org\/10.1016\/j.seizure.2017.09.021.","journal-title":"Seizure."},{"issue":"3","key":"1212_CR121","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/pch\/16.3.147","volume":"16","author":"M Ramsay","year":"2011","unstructured":"Ramsay M, Martel C, Porporino M, Zygmuntowicz C. The Montreal Children\u2019s Hospital Feeding Scale: a brief bilingual screening tool for identifying feeding problems. Paediatr Child Health. 2011;16(3):147-e17. https:\/\/doi.org\/10.1093\/pch\/16.3.147.","journal-title":"Paediatr Child Health"},{"issue":"8","key":"1212_CR122","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800\u201312. https:\/\/doi.org\/10.1097\/00005650-200108000-00006.","journal-title":"Med Care"},{"key":"1212_CR123","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.yebeh.2018.11.029","volume":"90","author":"C Sinoo","year":"2019","unstructured":"Sinoo C, de Lange IM, Westers P, Gunning WB, Jongmans MJ, Brilstra EH. Behavior problems and health-related quality of life in Dravet syndrome. Epilepsy Behav. 2019;90:217\u201327. https:\/\/doi.org\/10.1016\/j.yebeh.2018.11.029.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1212_CR124","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ejpn.2019.02.014","volume":"23","author":"A Strzelczyk","year":"2019","unstructured":"Strzelczyk A, Kalski M, Bast T, et al. Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: a prospective, multicenter study from Germany. Eur J Paediatr Neurol. 2019;23(3):392\u2013403. https:\/\/doi.org\/10.1016\/j.ejpn.2019.02.014.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"1212_CR125","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42466-022-00186-9","volume":"4","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Kurlemann G, Bast T, et al. Exploring the relationships between composite scores of disease severity, seizure-freedom and quality of life in Dravet syndrome. Neurol Res Pract. 2022;4(1):22. https:\/\/doi.org\/10.1186\/s42466-022-00186-9.","journal-title":"Neurol Res Pract."},{"issue":"4","key":"1212_CR126","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/epi.17513","volume":"64","author":"JH Carroll","year":"2023","unstructured":"Carroll JH, Cross JH, Hickson M, Williams E, Aldridge V, Collinson A. A core outcome set for childhood epilepsy treated with ketogenic diet therapy (CORE-KDT study): international parent and health professional consensus. Epilepsia. 2023;64(4):919\u201336. https:\/\/doi.org\/10.1111\/epi.17513.","journal-title":"Epilepsia"},{"issue":"Pt A","key":"1212_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108953","volume":"137","author":"AT Berg","year":"2022","unstructured":"Berg AT, Kaat AJ, Gaebler-Spira D. Measuring the inch stones for progress: gross motor function in the developmental and epileptic encephalopathies. Epilepsy Behav. 2022;137(Pt A): 108953. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108953.","journal-title":"Epilepsy Behav"},{"key":"1212_CR128","doi-asserted-by":"publisher","first-page":"263300402412497","DOI":"10.1177\/26330040241249762","volume":"18","author":"J Hecker","year":"2024","unstructured":"Hecker J, Conecker G, Chapman C, et al. Patient-advocate-led global coalition adapting fit-for-purpose outcomes measures to assure meaningful inclusion of DEEs in clinical trials. Ther Adv Rare Dis. 2024;18:26330040241249760. https:\/\/doi.org\/10.1177\/26330040241249762.","journal-title":"Ther Adv Rare Dis."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01212-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01212-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01212-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:01:37Z","timestamp":1757512897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01212-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":128,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1212"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01212-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"22 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no specific funding for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A Swindler currently receives PhD funding from the SCN1A Horizons Study (IRAS ID: 295069) Award No. 324631. A Harper currently receives PhD funding from the SCN1A Horizons Study (IRAS ID: 295069) Award No. 324631. K Hendry declares no conflicts of interest. A Strzelczyk reports personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Longboard, Neuraxpharm, Stoke Therapeutics, Takeda, UCB, and UNEEG Medical. C Reilly declares no conflicts of interest. A Brunklaus has received honoraria for presenting at educational events, advisory boards and consultancy work for Biocodex, Encoded Therapeutics, Jazz\/GW Pharma, Servier, Stoke Therapeutics, and UCB\/Zogenix.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data for this paper is presented within the manuscript itself.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Adriana Swindler searched and appraised literature on the neuropsychology aspects of DS with attention to any evidence-based interventions, interpreted the literature, drafted and revised the manuscript. Alexander Harper searched and appraised literature on the medical (nonseizure) aspects of DS with attention to any evidence-based interventions, interpreted the literature, drafted and revised the manuscript. Kirsty Hendry searched and reviewed literature on nonseizure comorbidities of DS, supported the interpretation of the literature and revised the draft manuscript. Adam Strzelczyk supported the interpretation of literature on quality of life and revised the draft manuscript. Colin Reilly coordinated writing of the manuscript, supported the interpretation of literature, and revised the draft manuscript. Andreas Brunklaus initiated and coordinated writing of the manuscript, supported the interpretation of literature and revised the manuscript. All of the authors affirm that they have read and approve this final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}